Atara Biotherapeutics (ATRA) Non Operating Interest Expenses (2022 - 2026)

Atara Biotherapeutics (ATRA) has reported Non Operating Interest Expenses for 5 consecutive years, with $191000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 80.35% year-over-year to $191000.0; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (down 32.59% YoY), and the FY2025 full-year result was $3.8 million, down 17.83% from the prior year.
• Non Operating Interest Expenses retreated to $191000.0 in Q2 2026 per ATRA's latest filing, from $830000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $1.4 million in Q3 2023 and bottomed at $4000.0 in Q1 2022.
• Historically, Non Operating Interest Expenses has averaged $838111.1 across 5 years, with a median of $994500.0 in 2024.
• The sharpest annual moves came in 2023 and 2026: Non Operating Interest Expenses jumped 33300.0% in 2023, then slumped 80.35% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $117000.0 in 2022, then surged by 905.13% to $1.2 million in 2023, then dropped by 13.52% to $1.0 million in 2024, then slipped by 12.09% to $894000.0 in 2025, then sank by 78.64% to $191000.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $191000.0, $830000.0, and $894000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.